SOX化疗方案治疗乳腺癌期间注射斑蝥酸钠维生素B<sub>6</sub>对肿瘤标志物及不良反应的影响

doi:10.3969/j.issn.1671-7171.2022.07.003

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1151 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨采用SOX化疗方案治疗乳腺癌期间注射斑蝥酸钠维生素B₆对患者肿瘤标志物及不良反应的影响。【方法】榆林市第二医院收治的82例乳腺癌晚期患者,随机分为对照组和观察组,每组41例。对照组采用单纯SOX化疗方案,观察组在对照组基础上联合斑蝥酸钠维生素B₆注射治疗。比较两组客观缓解率(RR),两组治疗前后免疫功能指标(CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺)及血清肿瘤标志物[糖类抗原153(CA-153)、癌胚抗原(CEA)、糖类抗原125(CA-125)]及肿瘤坏死因子-α(TNF-α)、白介素-17(IL-17)、巨噬细胞移动抑制因子(MIF)水平的变化,观察两组不良反应发生情况。【结果】观察组RR为95.12%(39/41),明显高于对照组的80.49%(33/41)(P<0.05)。两组治疗后CD3⁺、CD4⁺、CD4⁺/CD8⁺较治疗前升高(P<0.05),CD8⁺较治疗前降低(P<0.05);观察组治疗后CD3⁺、CD4⁺、CD4⁺/CD8⁺均高于对照组(P<0.05),CD8⁺低于对照组(P<0.05)。两组治疗后CA-153、CEA、CA-125及TNF-α、IL-17、MIF水平较治疗前降低(P<0.05);且观察组治疗后上述指标水平均低于对照组(P<0.05)。观察组不良反应总发生率为29.27%(12/41),与对照组的31.71%(13/41)比较,差异无统计学意义(P>0.05)。【结论】SOX化疗期间注射斑蝥酸钠维生素B₆可提高乳腺癌患者疗效,改善血清肿瘤标志物及免疫功能,且安全性高,值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	高庆东
	康锋

关键词 ：乳腺肿瘤/药物疗法, 抗肿瘤药, 维生素B₆, 癌胚抗原, 抗原, 肿瘤相关, 碳水化合物, 生物标记

Abstract：【Objective】 To investigate the effect of disodium cantharidinate and Vitamin B₆ injection on tumor markers and adverse reactions in patients with breast cancer treated with SOX chemotherapy. 【Methods】A total of 82 patients with advanced breast cancer were randomly divided into control group and observation group,with 41 cases in each group. The control group was treated with simple SOX chemotherapy,and the observation group was treated with disodium cantharidinate and Vitamin B₆ injection on the basis of the control group.Objective response rate (RR),immune function(CD3⁺,CD4⁺,CD8⁺,CD4⁺/CD8⁺) and serum tumor markers[carbohydrate antigen 153 (CA-153),carcinoembryonic antigen (CEA),carbohydrate antigen 125 (CA-125)] and changes in the levels of interleukin-17 (IL-17),macrophage migration inhibitory factor (MIF) and tumor necrosis factor-α(TNF-α) were compared between the two groups before and after treatment. The adverse reactions of the two groups were observed. 【Results】The RR of the observation group was 95.12% (39/41),which was significantly higher than that of the control group [80.49% (33/41)](P<0.05). After treatment,the levels of CD3⁺,CD4⁺,CD4⁺/CD8⁺ in the two groups were higher than those before treatment (P<0.05),and the levels of CD8⁺ were lower than those before treatment (P<0.05); After treatment,CD3⁺,CD4⁺,CD4⁺/CD8⁺ in the observation group were higher than those in the control group (P<0.05),and CD8⁺ was lower than those in the control group (P<0.05). The levels of IL-17,MIF,CA-153,CEA,CA-125 and TNF-α in both groups after treatment were lower than those before treatment (P<0.05); The levels of the above indexes in the observation group were lower than those in the control group after treatment (P<0.05). The total incidence of adverse reactions in the observation group was 29.27% (12/41),and there was no significant difference compared with 31.71% (13/41) in the control group (P>0.05). 【Conclusion】Injection of disodium cantharidinate and vitamin B₆ during SOX chemotherapy can improve the curative effect,serum tumor markers and immune function of patients with breast cancer,and the risk of adverse reactions is low,which is worthy of clinical promotion.

Key words： Breast Neoplasms/DT Antineoplastic Agents Vitamin B₆ Carcinoembryonic Antigen Biomarkers Antigens, Tumor-Associated, Carbohydrate Biomarkers

收稿日期: 2022-02-14

中图分类号:

R737.9

基金资助:陕西省卫生健康科研基金项目(编号:20180007)

通讯作者: **E-mail:77145032@qq.com

引用本文:

高庆东, 康锋. SOX化疗方案治疗乳腺癌期间注射斑蝥酸钠维生素B₆对肿瘤标志物及不良反应的影响[J]. 医学临床研究, 2022, 39(7): 969-972.
GAO Qing-dong, KANG Feng. Effects of Disodium Cantharidinate and Vitamin B₆ Injection on Tumor Markers and Adverse Reactions during SOX Regimen in the Treatment of Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 969-972.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.07.003 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I7/969